Trial Profile
A retrospective multi-institutional study assessing risk factors in patients treated with adjuvant imatinib therapy for gastrointestinal stromal tumors with suspicious/obvious tumor spillage
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2016
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 21 Jul 2016 New trial record
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology